Literature DB >> 26791118

Synchronous colonic lymphoma and adenocarcinoma in a patient with Crohn's disease, treated with thiopurine therapy and a TNFα inhibitor: a challenge to Occam's razor.

Rowan Daniel Beaumont Bell1, Kieran John Moriarty1.   

Abstract

A 52-year-old man with Crohn's disease, treated with thiopurine therapy and a tumour necrosis factor (TNF) α inhibitor, attended for surveillance colonoscopy, which revealed a transverse colon mass. Biopsies of this lesion showed a diffuse large B-cell lymphoma. CT scan demonstrated this lesion, an additional caecal mass and multiple metastases. A supraclavicular lymph node was removed and demonstrated metastatic adenocarcinoma, consistent with a synchronous caecal primary. At multidisciplinary oncological, haematological, histopathological, gastroenterological, radiological and palliative care assessment, the metastatic adenocarcinoma was deemed to carry a grave prognosis. Following sensitive discussion, the patient opted for palliative care and died several weeks later. Occam's razor, the principle that 'complexity should not be assumed unnecessarily', is a medical school doctrine. Occasionally, however, dual diagnoses do arise. Recognition, as in this case, may prove critical in informed decision-making, both by doctors and, most importantly, by patients, about prognosis and optimal patient care, especially end-of-life care. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26791118      PMCID: PMC4735391          DOI: 10.1136/bcr-2015-212464

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  In memory of William of Occam.

Authors:  M Wildner
Journal:  Lancet       Date:  1999 Dec 18-25       Impact factor: 79.321

2.  Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

Authors:  Stephen B Hanauer; Carrie L Wagner; Mohan Bala; Lloyd Mayer; Suzanne Travers; Robert H Diamond; Allan Olson; Warren Bao; Paul Rutgeerts
Journal:  Clin Gastroenterol Hepatol       Date:  2004-07       Impact factor: 11.382

3.  European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies.

Authors:  Vito Annese; Laurent Beaugerie; Laurence Egan; Livia Biancone; Claus Bolling; Christian Brandts; Daan Dierickx; Reinhard Dummer; Gionata Fiorino; Jean Marc Gornet; Peter Higgins; Konstantinos H Katsanos; Loes Nissen; Gianluca Pellino; Gerhard Rogler; Franco Scaldaferri; Edyta Szymanska; Rami Eliakim
Journal:  J Crohns Colitis       Date:  2015-08-20       Impact factor: 9.071

4.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Authors:  Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts
Journal:  Gut       Date:  2007-01-17       Impact factor: 23.059

5.  Screening and surveillance colonoscopy in chronic Crohn's colitis.

Authors:  S Friedman; P H Rubin; C Bodian; E Goldstein; N Harpaz; D H Present
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

6.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

Review 7.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  Prevention of cancer in IBD - a balancing act.

Authors:  J Mill; I C Lawrance
Journal:  Minerva Gastroenterol Dietol       Date:  2013-09

9.  Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

Authors:  David S Kotlyar; James D Lewis; Laurent Beaugerie; Ann Tierney; Colleen M Brensinger; Javier P Gisbert; Edward V Loftus; Laurent Peyrin-Biroulet; Wojciech C Blonski; Manuel Van Domselaar; Maria Chaparro; Sandipani Sandilya; Meenakshi Bewtra; Florian Beigel; Livia Biancone; Gary R Lichtenstein
Journal:  Clin Gastroenterol Hepatol       Date:  2014-05-28       Impact factor: 11.382

10.  Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Authors:  Corey A Siegel; Sadie M Marden; Sarah M Persing; Robin J Larson; Bruce E Sands
Journal:  Clin Gastroenterol Hepatol       Date:  2009-01-24       Impact factor: 11.382

View more
  1 in total

Review 1.  Synchronous colonic adenoma and intestinal marginal zone B-cell lymphoma associated with Crohn's disease: a case report and literature review.

Authors:  Amal Bennani; Ghizlane Kharrasse; Miry Achraf; Khanoussi Wafa; Ismaili Zahi; Kamaoui Imane; Bouziane Mohamed
Journal:  BMC Cancer       Date:  2019-10-17       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.